drugset / Trial / NCT01932502

Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy

NCT01932502

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to examine the clinical safety, tolerability, and efficacy of clobazam (Onfi) when it replaces the pre-existing clonazepam therapy in patients with refractory epilepsy.

Timeline

Start
2013-02
Primary completion
2017-06
Completion
2017-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Clobazam Small molecule 40 mg
Subject Clobazam Small molecule 60 mg

Indications